Characterization of TP53 mutations in low‐grade myelodysplastic syndromes and myelodysplastic syndromes with a non‐complex karyotype

Although commonly associated with high‐grade myelodysplastic syndrome (MDS) and MDS with a complex karyotype, TP53 mutations also occur in low‐grade MDS and MDS with a non‐complex karyotype. In latter cases, their clinicopathological features and the characteristics of TP53 mutations remain poorly characterized.

[1]  Satoru Miyano,et al.  Clonal evolution in myelodysplastic syndromes , 2017, Nature Communications.

[2]  T. Haferlach,et al.  The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases , 2017, Leukemia.

[3]  Christopher A. Miller,et al.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.

[4]  M. Walter,et al.  ‘CHIP’ping away at clonal hematopoiesis , 2016, Leukemia.

[5]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[6]  H. Votavova,et al.  TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes , 2016, Oncotarget.

[7]  K. Pradhan,et al.  High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort , 2016, Leukemia.

[8]  S. Nahas,et al.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.

[9]  H. Kantarjian,et al.  TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases , 2015, Journal of Hematology & Oncology.

[10]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[11]  D. Neuberg,et al.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.

[12]  C. Preudhomme,et al.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.

[13]  L. Attardi,et al.  Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.

[14]  M. Cazzola,et al.  The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.

[15]  O. Abdel-Wahab,et al.  Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia , 2013, Haematologica.

[16]  G. Mufti,et al.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.

[17]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[19]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[20]  A. Tefferi,et al.  Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.

[21]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[22]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Varda Rotter,et al.  Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. , 2011, Genes & cancer.

[24]  T. Graubert.  Therapy-related myelodysplastic syndrome: models and genetics. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  M. Andersen,et al.  Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. , 2002, Blood.

[26]  M. Higashiyama,et al.  Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer , 1998, Oncogene.

[27]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[28]  M. Benito,et al.  p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. , 1997, British Journal of Cancer.